Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 774 of 5804
-
Could skipping radiation be just as effective for rectal cancer?
Disease control Recruiting nowThis study is a non-inferiority phase III randomised trial comparing preoperative chemotherapy alone (modified FOLFIRINOX) to chemotherapy followed by chemoradiotherapy in patients with primary resectable locally advanced rectal cancer. The primary endpoint of the study is 3-year…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo shows promise for Hard-to-Treat lung cancer
Disease control CompletedThis is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treat…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Pancreatic cancer trial combines chemo with immune boosters
Disease control CompletedThis study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1 antibody, pembrolizumab, with and without study drug…
Phase: PHASE2 • Sponsor: Lei Zheng • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug shows promise for rare Muscle-Weakening disease
Disease control CompletedThe purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (MG).
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Could a rheumatoid arthritis drug calm a rare brain disease?
Disease control CompletedThe primary objective of this study is to assess safety as well as efficacy of baricitinib, a Janus Kinase (JAK) inhibitor, in patients with Aicardi Goutières Syndrome (AGS), a multisystem heritable disorder of the innate immunity resulting in excessive interferon production
Phase: PHASE2 • Sponsor: Adeline Vanderver, MD • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Bladder cancer umbrella trial tests immunotherapy combos
Disease control CompletedA Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with MIBC and in participants with locally advanced or metastatic Urothelial Carcinoma (UC) who have progressed during or following a platinum-containing regimen. The study is designed with the fle…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Radioactive therapy shows promise for tough prostate cancer
Disease control CompletedThis clinical trial was done to show whether a radioactive drug (I-131-1095) that binds to prostate-specific membrane antigen (PSMA) is useful in treating metastatic prostate cancer that is positive for PSMA. The trial enrolled men whose PSMA-positive metastatic prostate cancer h…
Phase: PHASE2 • Sponsor: Progenics Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Shorter, stronger radiation for prostate cancer shows promise in new trial
Disease control OngoingThis phase III trial studies how well hypofractionated radiation therapy works compared to the conventional one in treating patients with prostate cancer. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Hypofractionated radiation therapy delivers h…
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo therapy targets rare salivary gland cancer
Disease control OngoingA Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.
Phase: PHASE2 • Sponsor: Manish Patel • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Can facebook help prevent HIV in rural appalachia?
Prevention CompletedThe overall aim of this R34 application is to adapt and feasibility test an evidence-based HIV prevention education for high-risk, underserved rural women in Appalachia. This study has potential to make a significant contribution to science by advancing knowledge on the use of so…
Phase: NA • Sponsor: Michele Staton • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise in advanced bladder cancer trial
Disease control OngoingThis is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study designed to compare the efficacy and safety of tislelizumab + either cisplatin or carboplatin + gemcitabine versus placebo+ either cisplatin or carboplatin + gemcitabine in approximately 420 partic…
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo shows promise against tough head and neck cancer
Disease control CompletedThe investigators hypothesize that inhibition of angiogenesis and PD-1 will be more effective than inhibition of PD-1 alone. The first step in pursuing proof of this hypothesis is to establish the safety and feasibility of combining ramucirumab with pembrolizumab, therefore the f…
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug shows promise for rare skin disease over nearly 5 years
Disease control OngoingThis study is open to people with generalized pustular psoriasis (GPP). People can only take part if they have completed treatment in a previous study with spesolimab (1368-0013 or 1368-0027). The goal of this study is to find out how well people with GPP tolerate long-term trea…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New heart valve fix without cutting chest shows promise for High-Risk patients
Disease control Recruiting nowto evaluate the safety and performance of the HighLife 28mm transcatheter, trans-septal Mitral Valve in patients with moderate-severe or severe mitral regurgitation who are at high risk for surgical treatment.
Phase: NA • Sponsor: HighLife SAS • Aim: Disease control
Last updated Jun 26, 2026 17:02 UTC
-
DNA-Guided heart therapy could prevent thousands of heart attacks
Disease control OngoingThe aim of this study is to assess the efficacy and safety of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel in non-carriers of a CYP2C19\*2 or \*3 allele and ticagrelor in carriers of a CYP2C19\*2 or \*3 allele in patients treated with new generat…
Phase: NA • Sponsor: Beijing Anzhen Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill could help kids with severe eczema
Disease control OngoingThe reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo may extend life in tough pancreatic cancer
Disease control CompletedThis study aims to evaluate whether the combination of gemcitabine and paclitaxel allows to improve the overall survival compared to gemcitabine alone, in patients with metastatic Pancreatic Ductal Adenocarcinoma (PDAC) after FOLFIRINOX failure or intolerance.
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New hope for immunocompromised patients with severe parainfluenza
Disease control Recruiting nowThis study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Phase: PHASE3 • Sponsor: Ansun Biopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug shows promise in Early-Stage High-Risk leukemia trial
Disease control OngoingOpen label, single arm, multicenter phase II trial.
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New antibody shows promise for rare blood cancers
Disease control CompletedThis is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
Phase: PHASE2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC